1 FTSE 100 share I think may help make you a million

David Barnes asks whether an investment in this FTSE 100 healthcare stalwart could help make you a million as part of a diverse share portfolio?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The share price of FTSE 100 listed medical devices company Smith & Nephew (LSE: SN) has steadily climbed for a number of years, reaching a peak of over 2,000p earlier this year. £100,000 invested back when Westlife topped the charts with ‘I Have A Dream’ at the Millennium would have risen to a cool million by February 2020.

However, since February, revenues have been hit by the coronavirus pandemic and the share price now sits around 25% below its year high. For new investors, does this dip represent a buying opportunity to make your million?

FTSE 100 stalwart

Smith & Nephew has been a constituent member of the FTSE 100 since 2001. At just under 2%, its dividend might not be much to write home about but it’s progressive and the company has paid a dividend every year since before World War II. In a sea of dividend cuts, such reliability coupled with a cast iron balance sheet is reassuring.

I’m also bullish in the long-term growth story for Smith & Nephew. Just under half its revenue is generated from orthopaedics, so things like knee joints, braces and hip replacements. The remainder is from a combination of wound management, trauma services and increasingly surgical robotics.

As my Foolish colleague Edward Sheldon points out, with the world population growing and people living longer, the market opportunity for this FTSE 100 share is rapidly expanding.

Recession-proof, but not pandemic-proof

Whilst healthcare can largely weather a recession, the coronavirus severely limited elective surgeries. In a July trading update, Smith & Nephew confirmed second-quarter revenues would decline around 29% as a result. This mainly impacted its orthopaedic and sports medicine divisions as people chose to delay their surgery.

However, the FTSE 100 company announced its revenues were strongly correlated to the easing of lockdown restrictions and performance had improved during each month of the quarter.

Broker Berenburg certainly sees a bright future, reiterating a buy rating on this FTSE 100 stock with a target price of 2,165p. It believes that as elective surgeries resume, revenues should return to ‘near-normal’ levels by 2021. From then on, Berenburg predicts continued above market revenue growth.

Could history repeat itself?

If I had £100,000 to invest, I would not be advocating putting it all in one share of course. But I do think Smith & Nephew is one of the best FTSE 100 growth shares. With a P/E ratio of 19, and after the recent dip in share price, I see a lot of value here – and with a 20-year plus investing horizon ahead of me, Smith & Nephew is part of my diversified portfolio in my own quest to make a million.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

David Barnes owns shares in Smith & Nephew. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

10% dividend growth! 2 FTSE 100 stocks tipped to supercharge cash payouts

These FTSE 100 stocks have strong records of dividend growth. And they're expected to keep on delivering, as Royston Wild…

Read more »

Investing Articles

Down 17% in a month and yielding 7.39%! Is this FTSE 100 share a screaming buy for me?

When Harvey Jones bought Taylor Wimpey last year he thought this FTSE 100 share was a brilliant long-term buy-and-hold. Has…

Read more »

Investing Articles

Here’s how I’m using a £20k ISA to target £11k+ in income 30 years from now

Is it realistic to put £20k in an ISA now and earn over half that amount every year in passive…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

If I could only keep 5 UK stocks from my portfolio I’d save these

Harvey Jones is running through his portfolio of top UK stocks to see which ones he couldn't bear to do…

Read more »

Midnight is celebrated along the River Thames in London with a spectacular and colourful firework display.
Investing Articles

I’m aiming for a million buying unexciting shares!

By investing regularly in long-established, proven and even rather dull businesses, this writer plans to aim for a million. Here's…

Read more »

Investing Articles

3 things to consider before you start investing

Our writer draws on his stock market experience to consider a few vital lessons he would use to start investing…

Read more »

Investing Articles

Will this lesser-known £28bn growth stock be joining the FTSE 100 soon?

As the powers that be plan a reorganisation of Footsie listing rules, this massive under-the-radar growth stock could find its…

Read more »

Investing Articles

Fools wouldn’t touch these 5 FTSE 350 flops with a bargepole – how come I own 3 of them?

Harvey Jones took a chance on three struggling FTSE 350 stocks in the hope that they'd stage a dramatic recovery.…

Read more »